Ginsenoside Rb1 has the potential for use as an antiobesity therapeutic agent that functions by modulating obesity-induced inflammation and improving central leptin sensitivity in HF diet-induced obesity. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.